Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...

Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...

In a report released today, Emily Field from Barclays maintained a Buy rating on Genmab A/S (0MGB – Research Report), with a price target of ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...

Equities researchers at William Blair issued their Q3 2025 earnings per share estimates for Genmab A/S in a research note issued on Thursday, February 13th. William Blair analyst M. Phipps forecasts ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ ... continue to grapple with how rate changes can affect stock valuations and overall economic conditions.